A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Intrathecally Administered ALN-APP in Patients with Cerebral Amyloid Angiopathy (CAA).
Apply to Participate
If you are interested in participating in this study, please complete the following preliminary qualification form.
We will follow-up with you after we have received your submission.